Skip to content

H.R. 1352 · 118th Congress (2023–2025)

Increasing Access to Biosimilars Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Show official title

To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 1352’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Richard Hudson (R-NC-9)
Policy area
Health
Subjects
  • Congressional oversight
  • Government studies and investigations
  • Health care costs and insurance
  • Medicare
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 8 committee actions · Mar 3, 2023 – Dec 17, 2024
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    4. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee by Voice Vote.

      Sources
    5. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    6. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    7. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.

      Sources
    8. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 3, 2023 · Markup Dec 5, 2023 · Markup Dec 6, 2023
    1. Dec 5, 2023 · Markup

  2. HouseHealthReferred Mar 10, 2023 · Markup Nov 15, 2023 · Reported Nov 15, 2023
    1. Nov 15, 2023 · Meeting

    2. Oct 19, 2023 · Meeting

  3. HouseWays and MeansReferred Mar 3, 2023
  4. HouseHealthReferred Dec 17, 2024

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Increasing Access to Biosimilars Act of 2023

    Display title, Short title · Introduced in House

  2. To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.

    Official title · Introduced in House